Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1142524 pilot safety study in stable left-ventricular dysfunction after myocardial infarction
2014-005297-12Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of fulacimstat in left ventricular dysfunction and myocardial infarction (MI) (8 arms), sponsored by Bayer. Primary endpoint: Safety and tolerability. Started Mar 2015; status: completed.
02
Drugs
fulacimstat
03
Conditions
left ventricular dysfunctionmyocardial infarction (MI)
Beyond the preview
Go deeper on 2014-005297-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005297-12.